Kansas City, Kan- From genetic breakthroughs to lifestyle-focused care, advancements in treating cystic fibrosis (CF) and pulmonary fibrosis (PF) are helping patients live longer, fuller lives—thanks in large part to ongoing clinical research at The University of Kansas Health System.
CF is a genetic disorder that causes thick, sticky mucus to build up in the lungs and other organs, leading to respiratory and digestive problems.
A newer medication called Trikafta works by correcting the malfunctioning CFTR protein caused by mutations in the CF gene—dramatically improving lung function, reducing hospitalizations, and increasing life expectancy.
Andrew Sabatino and Sarah Johnson both saw dramatic improvements in their health and quality of life as a result of the medications.
While CF is a condition present from birth, pulmonary fibrosis is often diagnosed later in life. PF causes progressive scarring of the lung tissue, which can make breathing difficult and ultimately lead to respiratory failure. The disease can be caused by environmental exposures, autoimmune conditions, or unknown factors.
Craig Ackerson and Madonna Mergenmeier, both PF patients, stress the importance of early diagnosis and staying physically active to maintain lung capacity.
Both have participated in clinical trials at The University of Kansas Health System. Learn more here:
Cystic Fibrosis Care Center | The University of Kansas Health System
